Comprehensive proteomic meta-analysis identifies novel proteomics alterations in proliferative diabetic retinopathy.

Exp Eye ResMay 27, 2026 (epub)
Clinical ResearchOphthalmology

Pei Lin, Ningzhi Zhang, Wenxi Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined proteomic alterations in patients with proliferative diabetic retinopathy (PDR) by analyzing five datasets. The study identified 681 differentially expressed proteins, with significant pathways related to complement cascades and extracellular matrix. The findings suggest potential biomarkers and therapeutic targets for PDR.

Key findings

  • 681 differentially expressed proteins were identified in patients with PDR.
  • Top three upregulated proteins were found in only one dataset.
  • Significant pathways included complement and coagulation cascades.
  • Western blot validation showed downregulation of APP and CNTN1 in diabetic mice.

Why it matters

Understanding the proteomic alterations in PDR can help identify potential biomarkers and therapeutic targets, which may improve patient management and treatment outcomes in this vision-threatening condition.

Source

PubMed · PMID 42208844

Published in Exp Eye Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.